128 related articles for article (PubMed ID: 791316)
1. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Pharmacol; 1975 Jan; 53(1):121-5. PubMed ID: 1125484
[TBL] [Abstract][Full Text] [Related]
3. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
[TBL] [Abstract][Full Text] [Related]
4. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
5. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
Boullin DJ; Grimes RP
Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
[TBL] [Abstract][Full Text] [Related]
6. Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.
Baldacci M; Baldacci M; Bergel TD; Born GV; Hickman M
Br J Pharmacol; 1980 May; 69(1):113-8. PubMed ID: 7378650
[TBL] [Abstract][Full Text] [Related]
7. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
Michal F; Motamed M
Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
[TBL] [Abstract][Full Text] [Related]
8. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Youdim MB; Hefez A; Oppenheim B
Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
[TBL] [Abstract][Full Text] [Related]
9. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
[TBL] [Abstract][Full Text] [Related]
10. Platelet aggregation and chlorpromazine therapy.
Boullin DJ; Know JM; Peters JR; Orr MW; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1978 Dec; 6(6):538-40. PubMed ID: 728326
[No Abstract] [Full Text] [Related]
11. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
[TBL] [Abstract][Full Text] [Related]
12. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Orr MW; Boullin DJ
Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
[TBL] [Abstract][Full Text] [Related]
13. Acetal phosphatidic acids: novel platelet aggregating agents.
Brammer JP; Maguire MH; Walaszek EJ; Wiley RA
Br J Pharmacol; 1983 May; 79(1):157-66. PubMed ID: 6871540
[TBL] [Abstract][Full Text] [Related]
14. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
Glusa E; Markwardt F
Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
[TBL] [Abstract][Full Text] [Related]
16. 5-hydroxytryptamine and platelet aggregation.
De Clerck FF; Herman AG
Fed Proc; 1983 Feb; 42(2):228-32. PubMed ID: 6822293
[TBL] [Abstract][Full Text] [Related]
17. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Boullin DJ; Orr MW
Br J Clin Pharmacol; 1976 Oct; 3(5):929-33. PubMed ID: 973989
[TBL] [Abstract][Full Text] [Related]
18. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
19. Platelet function after the administration of chlorpromazine to human subjects.
Warlow C; Ogston D; Douglas AS
Haemostasis; 1976; 5(1):21-6. PubMed ID: 1269995
[TBL] [Abstract][Full Text] [Related]
20. Actions and interactions of ADP, 5- HT, histamine and PAF on equine platelets.
Bailey SR; Andrews MJ; Elliott J; Cunningham F
Res Vet Sci; 2000 Apr; 68(2):175-80. PubMed ID: 10756136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
